Namitecan: a hydrophilic camptothecin with a promising preclinical profile.

Abstract

Camptothecins are still among the most widely prescribed and effective anticancer drugs. Unfortunately, important drawbacks including water insolubility, lactone instability, reversibility of the drug-target interaction, drug resistance and toxicity are responsible for treatment failure and often require suspension of the drug administration itself. In order to overcome such drawbacks, several options in chemical manipulation of natural camptothecin have been explored, and effective compounds have been identified in a novel series of 7-oxyiminomethyl derivatives. Among the compounds of this series, the hydrophilic derivative namitecan (7 (2-aminoethoxy) iminomethyl camptothecin) has been selected for further development. The relevant features of namitecan are: 1) marked cytotoxic potency - likely related to multiple factors, including i) a potent inhibition of topoisomerase I, ii) a persistent stabilization of the cleavable complex, iii) an increased intracellular accumulation, and iv) a peculiar subcellular localization; 2) enhanced lactone stability and favorable pharmacokinetics; 3) remarkable antitumor efficacy in a large panel of human tumor xenografts (including tumor models relatively resistant to topotecan and irinotecan), particularly on squamous cell carcinomas. The clinical development of namitecan is currently ongoing. Namitecan exhibited an acceptable toxicity profile, with neutropenia being the dose-limiting toxic effect, and clinical benefit was appreciable in patients with different tumor types, particularly bladder and endometrium carcinomas. In this article, we review the relevant features of namitecan, with particular reference to its advantages compared with the two analogues (topotecan and irinotecan) approved for clinical use.

• Authors: G L Beretta, V Zuco, M De Cesare, P Perego, N Zaffaroni
• Journal: Current medicinal chemistry (Curr Med Chem) Vol. 19 Issue 21 Pg. 3488-501 ( 2012) ISSN: 1875-533X [Electronic] United Arab Emirates
• PMID: 22680917 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Enzyme Inhibitors
• DNA Topoisomerases, Type I
• namitecan
• Camptothecin

Topics

• Animals
• Antineoplastic Agents (chemistry, pharmacology)
• Camptothecin (analogs & derivatives, chemistry, pharmacology)
• Cell Proliferation (drug effects)
• DNA Topoisomerases, Type I (metabolism)
• Drug Screening Assays, Antitumor
• Enzyme Inhibitors (chemistry, pharmacology)
• Humans
• Models, Molecular
• Structure-Activity Relationship